Clostridium difficile-associated diarrhea in the oncology patient

Journal of Oncology Practice

Volumn 13, Issue 1, 2017, Pages 25-30

  Neemann, Kari ^a   Freifeld, Alison ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; CANCER PATIENT; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; EPIDEMIC; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INFECTION RISK; INTESTINE FLORA; MORBIDITY; MORTALITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; DIARRHEA; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PATHOGENICITY;

CLOSTRIDIUM DIFFICILE; DIARRHEA; HUMANS; RISK FACTORS;

EID: 85011371140     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.018614     Document Type: Review

References (59)

1. Kelly CP, LaMont JT: Clostridium difficile-more difficult than ever. N Engl J Med 359:1932-1940, 2008
2. Bartlett JG, Gerding DN: Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46:S12-S18, 2008 (suppl 1)
3. Chopra T, Chandrasekar P, Salimnia H, et al: Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 25: E82-E87, 2011
4. Loo VG, Bourgault AM, Poirier L, et al: Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693-1703, 2011
5. Gorschl üter M, Glasmacher A, Hahn C, et al: Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:786-791, 2001
6. Arango JI, Restrepo A, Schneider DL, et al: Incidence of Clostridium difficileassociated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 37: 517-521, 2006
7. Dubberke ER, Reske KA, Srivastava A, et al: Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: Risk associations, protective associations, and outcomes. Clin Transplant 24:192-198, 2010
8. Willems L, Porcher R, Lafaurie M, et al: Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation:Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 18:1295-1301, 2012
9. Alonso CD, Marr KA: Clostridium difficile infection among hematopoietic stem cell transplant recipients: Beyond colitis. Curr Opin Infect Dis 26:326-331, 2013
10. Trifilio SM, Pi J, Mehta J: Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 19:405-409, 2013
11. Neemann K, Minhas V, Loberiza FR, et al: Transplant related outcomes in patients with hematopoietic stem cell transplant with Clostridium difficile associated diarrhea. Leuk Lymphoma 56:260-262, 2015
12. Galdys AL, Nelson JS, Shutt KA, et al: Prevalence and duration of asymptomatic Clostridium difficile carriage among healthy subjects in Pittsburgh, Pennsylvania. J Clin Microbiol 52:2406-2409, 2014
13. Cohen SH, Gerding DN, Johnson S, et al: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455, 2010
14. Kelly CP, Pothoulakis C, LaMont JT: Clostridium difficile colitis. N Engl J Med 330:257-262, 1994
15. Huelsenbeck J, Dreger SC, Gerhard R, et al: Upregulation of the immediate early gene product RhoB by exoenzyme C3 from Clostridium limosum and toxin B from Clostridium difficile. Biochemistry 46:4923-4931, 2007
16. McDonald LC, Killgore GE, Thompson A, et al: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433-2441, 2005
17. Loo VG, Poirier L, Miller MA, et al: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442-2449, 2005
18. MacCannell DR, Louie TJ, Gregson DB, et al: Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44:2147-2152, 2006
19. Zhang L, Dong D, Jiang C, et al: Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe 34:1-7, 2015
20. Taur Y, Pamer EG: Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat Med 20:246-247, 2014
21. Hautmann MG, Hipp M, Kölbl O: Clostridium difficile-associated diarrhea in radiooncology: An underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 6:89, 2011
22. Anand A, Glatt AE: Clostridium difficile infection associated with antineoplastic chemotherapy: A review. Clin Infect Dis 17:109-113, 1993
23. HowellMD,Novack V, Grgurich P, et al: Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784-790, 2010
24. Bishop KD, Castillo JJ: Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 53:1617-1619, 2012
25. McCaleb RV, Gandhi AS, Clark SM, et al: Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center. Ann Pharmacother 50:541-547, 2016
26. Rodriguez Garzotto A, M erida Garcia A, Muñoz Unceta N, et al: Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 23:1569-1577, 2015
27. Stringer AM: Interaction between host cells and microbes in chemotherapyinduced mucositis. Nutrients 5:1488-1499, 2013
28. Leslie JL, Huang S, Opp JS, et al: Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. Infect Immun 83:138-145, 2015
29. Fainstein V, Bodey GP, Fekety R: Relapsing pseudomembranous colitis associated with cancer chemotherapy. J Infect Dis 143:865, 1981
30. Cudmore M, Silva J, Fekety R: Clostridial enterocolitis produced by methotrexate in hamsters, abstracted. Clin Res 27:383, 1979
31. Husain A, Aptaker L, Spriggs DR, et al: Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 71:104-107, 1998
32. Emoto M, Kawarabayashi T, Hachisuga MD, et al: Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61:369-372, 1996
33. Gifford AH, Kirkland KB: Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 25:751-755, 2006
34. Fuereder T, Koni D,Gleiss A, et al: Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients. Sci Rep 6:31498, 2016
35. Planche T,Wilcox MH: Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin North Am 29:63-82, 2015
36. Chen S, Gu H, Sun C, et al: Rapid detection of Clostridium difficile toxins and laboratory diagnosis of Clostridium difficile infections. Infection doi:10.1007/s15010-016-0940-9 [epub ahead of print on September 6, 2016]
37. Erb S, Frei R, Strandén AM, et al: Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. Clin Microbiol Infect 21:998.e9-998.e15, 2015
38. Goldenberg SD, Cliff PR, Smith S, et al: Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J Hosp Infect 74:48-54, 2010
39. Bauer MP, Kuijper EJ, van Dissel JT: European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 15:1067-1079, 2009
40. Wang MS, Evans CT, Rodriguez T, et al: Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol 34:127-132, 2013
41. Zar FA, Bakkanagari SR, Moorthi KM, et al: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302-307, 2007
42. Musher DM, Aslam S, Logan N, et al: Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586-1590, 2005
43. Baden LR, Swaminathan S, Angarone M, et al: Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:882-913, 2016
44. Cornely OA, Miller MA, Fantin B, et al: Resolution of Clostridium difficileassociated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493-2499, 2013
45. Pozzoni P, Riva A, Bellatorre AG, et al: Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: A single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 107:922-931, 2012
46. Ehrhardt S, Guo N, Hinz R, et al: Saccharomyces boulardii to prevent antibioticassociated diarrhea: A randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis 3:ofw011, 2016
47. Cohen SA, Woodfield MC, Boyle N, et al: Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis 18: 699-705, 2016
48. Mehta A, Rangarajan S, Borate U: A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. Bone Marrow Transplant 48: 461-462, 2013
49. van Nood E, Vrieze A, Nieuwdorp M, et al: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407-415, 2013
50. Webb BJ, Brunner A, Ford CD, et al: Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 18:628-633, 2016
51. Dubberke E: Clostridium difficile infection: The scope of the problem. J Hosp Med 7:S1-S4, 2012 (suppl 3)
52. McFarland LV, Elmer GW, Surawicz CM: Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97: 1769-1775, 2002
53. Chung MS, Kim J, Kang JO, et al: Impact of malignancy on Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 35:1771-1776, 2016
54. Kinnebrew MA, Lee YJ, Jenq RR, et al: Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. PLoS One 9:e90158, 2014
55. Kamboj M, Xiao K, Kaltsas A, et al: Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: Strain diversity and outcomes associated with NAP1/027. Biol Blood Marrow Transplant 20:1626-1633, 2014
56. Song L, Zhao M, Duffy DC, et al: Development and validation of digital enzyme-linked immunosorbent assays for ultrasensitive detection and quantification of Clostridium difficile toxins in stool. J Clin Microbiol 53: 3204-3212, 2015
57. Huang B, Jin D, Zhang J, et al: Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool. J Clin Microbiol 52:1105-1111, 2014
58. Taur Y, Jenq RR, Perales MA, et al: The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124:1174-1182, 2014
59. Taur Y, Xavier JB, Lipuma L, et al: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55:905-914, 2012